Successful Treatment of Newly Developed, Intractable Digital Ulcers and Gangrene with Bosentan in Systemic Sclerosis.
10.4078/jrd.2016.23.3.193
- Author:
Hee Sang TAG
1
;
Sung Min JUN
;
Seung Geun LEE
;
Eun Kyoung PARK
;
Dong Wan KOO
;
Geun Tae KIM
Author Information
1. Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea. gtah@hanmail.net
- Publication Type:Case Report
- Keywords:
Bosentan;
Systemic scleroderma;
Gangrene
- MeSH:
Acro-Osteolysis;
Gangrene*;
Humans;
Receptors, Endothelin;
Scleroderma, Systemic*;
Ulcer*
- From:Journal of Rheumatic Diseases
2016;23(3):193-197
- CountryRepublic of Korea
- Language:English
-
Abstract:
In systemic sclerosis, digital ulcers and gangrene are somewhat common clinical characteristics of obliterative vasculopathy. These manifestations increase morbidities, such as pain, infections, and acroosteolysis. However, patient responses to the appropriate treatments are often inadequate. We treated a patient with systemic sclerosis who had a refractory digital ulcer and gangrene with bosentan, an endothelin receptor antagonist, and observed improvement. Here we systematically review this case.
